147 related articles for article (PubMed ID: 8266611)
1. Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
Urol Int; 1993; 51(4):204-8. PubMed ID: 8266611
[TBL] [Abstract][Full Text] [Related]
2. The role of serum laminin P1 in the diagnosis of transitional cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Bruins JL; Kester AD; Janknegt R
Eur Urol; 1992; 21(3):240-4. PubMed ID: 1499633
[TBL] [Abstract][Full Text] [Related]
3. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.
Heicappell R; Schostak M; Müller M; Miller K
Scand J Clin Lab Invest; 2000 Jul; 60(4):275-82. PubMed ID: 10943597
[TBL] [Abstract][Full Text] [Related]
5. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.
Vlahou A; Schellhammer PF; Mendrinos S; Patel K; Kondylis FI; Gong L; Nasim S; Wright GL
Am J Pathol; 2001 Apr; 158(4):1491-502. PubMed ID: 11290567
[TBL] [Abstract][Full Text] [Related]
7. Value of serum laminin P1 as a diagnostic and monitoring parameter in transitional cell carcinoma of the bladder.
AbouFarha KM; Menheere PP; Nieman FH; Arends JW; Janknegt RA
Urol Int; 1992; 49(3):130-6. PubMed ID: 1466090
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of urinary hyaluronic acid and hyaluronidase in detection of bladder transitional cell carcinoma.
Jamshidian H; Hashemi M; Nowroozi MR; Ayati M; Bonyadi M; Najjaran Tousi V
Urol J; 2014 Mar; 11(1):1232-7. PubMed ID: 24595930
[TBL] [Abstract][Full Text] [Related]
10. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder.
Heicappell R; Wettig IC; Schostak M; Müller M; Steiner U; Sauter T; Miller K
Eur Urol; 1999 Jan; 35(1):81-7. PubMed ID: 9933798
[TBL] [Abstract][Full Text] [Related]
11. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.
Mungan U; Kirkali G; Celebi I; Kirkali Z
Urology; 1996 Sep; 48(3):496-500. PubMed ID: 8804512
[TBL] [Abstract][Full Text] [Related]
12. Relation between basement membrane degradation and serum levels of laminin P1 in patients with transitional cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
Urol Int; 1993; 50(1):13-6. PubMed ID: 8434420
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of urinary soluble Fas in screening for bladder cancer.
Srivastava AK; Singh PK; Singh D; Dalela D; Rath SK; Bhatt ML
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e215-21. PubMed ID: 24576318
[TBL] [Abstract][Full Text] [Related]
14. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
15. Urine and serum cathepsin B concentrations in the transitional cell carcinoma of the bladder.
Kotaska K; Dusek P; Prusa R; Vesely S; Babjuk M
J Clin Lab Anal; 2012 Feb; 26(2):61-5. PubMed ID: 22467319
[TBL] [Abstract][Full Text] [Related]
16. Detection of autocrine motility factor in urine as a marker of bladder cancer.
Guirguis R; Schiffmann E; Liu B; Birkbeck D; Engel J; Liotta L
J Natl Cancer Inst; 1988 Oct; 80(15):1203-11. PubMed ID: 3138430
[TBL] [Abstract][Full Text] [Related]
17. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
18. Recovery of epidermal growth factor in voided urine of patients with bladder cancer.
Messing EM; Murphy-Brooks N
Urology; 1994 Oct; 44(4):502-6. PubMed ID: 7941190
[TBL] [Abstract][Full Text] [Related]
19. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
20. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
